China

Shanghai Henlius Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Shanghai Henlius Biotech, Inc. (2696 HK) – Expecting five NDA Approvals Within Two Years

Lead Product(s): HLX71

Therapeutic Area: Infections and Infectious Diseases Product Name: HLX71

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 13, 2020

Details:

The Company actively involves in development of anti-COVID-19 drugs with two candidates in pre-clinical phase, including HLX71 (S1 protein), and HLX70 (S1 protein).

Sinovac Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III

Lead Product(s): Inactivated vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Institut of Butantan

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 11, 2020

Details:

This collaboration focuses on the clinical development to advance the clinical trials of CoronaVac, Sinovac’s inactivated vaccine candidate against COVID-19 to Phase III.

Clover Biopharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

CEPI Announces COVID-19 Vaccine Development Partnership With Clover Biopharmaceuticals’ Australian Subsidiary

Lead Product(s): COVID-19 S-Trimer

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: CEPI

Deal Size: $3.5 million Upfront Cash: Undisclosed

Deal Type: Funding April 27, 2020

Details:

CEPI to provide funds to Clover Biopharmaceuticals Australia to support preparation and initiation of a phase 1 trial of Clover’s protein-based COVID-19 S-Trimer vaccine in Australia.

Stemirna Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Pilot testing of potential COVID-19 vaccine progresses

Lead Product(s): COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 17, 2020

Details:

The pilot testing of the vaccine for novel coronavirus, will be focused on animal toxicology and the vaccine's effectiveness. Clinical trials are expected to start in mid-April.

Clover Biopharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Clover and GSK Announce Research Collaboration

Lead Product(s): COVID-19 S-Trimer

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: GlaxoSmithKline

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 24, 2020

Details:

GSK will provide Clover with its pandemic adjuvant system for further evaluation of S-Trimer in preclinical studies.

Beijing Advaccine Biotechnology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China

Lead Product(s): INO-4800

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Inovio Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 30, 2020

Details:

The goal of this collaboration is to leverage Advaccine's expertise to run a Phase 1 trial in China in parallel with Inovio's clinical development efforts in the U.S.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. (2696 HK) – Expecting five NDA Approvals Within Two Years

Sinovac Biotech

Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III

Clover Biopharmaceutical

CEPI Announces COVID-19 Vaccine Development Partnership With Clover Biopharmaceuticals’ Australian Subsidiary

Stemirna Therapeutics

Pilot testing of potential COVID-19 vaccine progresses

Clover Biopharmaceutical

Clover and GSK Announce Research Collaboration

Beijing Advaccine Biotechnology

Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China